How to Choose the Right Blood Cancer Specialist in Shanghai — Lymphoma, Myeloma, Leukemia & More | CMCS Patient Guide

Overview

Blood cancers — lymphoma, multiple myeloma, leukemia, and related conditions — are among the most complex and rapidly evolving areas of oncology. Treatment decisions require deep expertise in molecular subtyping, novel agents, CAR-T cell therapy, stem cell transplantation, and increasingly, integrative medicine. Shanghai is home to some of the world's most experienced blood cancer specialists across every discipline. This guide, compiled by China Medical Concierge Shanghai (CMCS), helps international patients navigate their options based on their specific diagnosis and clinical situation.

Shanghai's Leading Blood Cancer Specialists at a Glance

How to Choose: Matching Your Diagnosis to the Right Specialist

🔵 Lymphoma & CAR-T Cell Therapy

For patients with lymphoma — particularly diffuse large B-cell lymphoma (DLBCL), T-cell lymphomas, follicular lymphoma, or relapsed/refractory disease requiring CAR-T therapy:

• Prof. Zhao Weili (Ruijin Hospital) — China's foremost lymphoma precision medicine specialist and the 2024 recipient of France's prestigious Charpak-Dubousset Prize from the French National Academy of Medicine — one of the highest international honors in medical science. As Vice President of Ruijin Hospital and Director of the Shanghai Institute of Hematology, Prof. Zhao has built China's most advanced lymphoma molecular subtyping and precision treatment program. Her expertise in DLBCL molecular classification (GCB vs. ABC), double-hit/triple-hit lymphoma, and T-cell lymphoma makes her the first choice for patients with complex or treatment-resistant lymphoma requiring the most precise diagnostic and therapeutic approach.
• Prof. Liu Peng (Zhongshan Hospital) — Director of the #1-ranked hematology department among Shanghai municipal hospitals and the physician who played a pivotal role in bringing China's first domestically approved lymphoma CAR-T product to market. For patients with relapsed/refractory large B-cell lymphoma who are candidates for CAR-T therapy, Prof. Liu's program offers unmatched experience in CAR-T delivery, patient selection, and toxicity management. His department also provides comprehensive myeloma treatment alongside its lymphoma expertise.

🟡 Multiple Myeloma & Plasma Cell Disorders

For patients with multiple myeloma, smoldering myeloma, AL amyloidosis, Waldenström macroglobulinemia, or other plasma cell disorders:

• Prof. Hou Jian (Renji Hospital) — Widely regarded as "China's Myeloma Master" and a member of the International Myeloma Working Group (IMWG) — the world's premier myeloma scientific body responsible for developing global diagnostic criteria and treatment guidelines. Prof. Hou has contributed to both Chinese and international myeloma guidelines and brings the deepest level of myeloma expertise available in Shanghai. The first choice for patients with newly diagnosed high-risk myeloma, relapsed/refractory disease, or rare plasma cell disorders requiring the most authoritative specialist opinion.
• Prof. Shi Jumei (Oriental Hospital) — Vice President of Oriental Hospital and Director of one of Shanghai's most competitive hematology departments, with extensive training at a top-tier US myeloma center. Prof. Shi's international training gives her a depth of expertise in novel agent therapy, CAR-T, and autologous stem cell transplantation for myeloma that is rare among Chinese hematologists. An excellent choice for patients who want both world-class myeloma expertise and access to the full spectrum of CAR-T and transplantation capabilities in a single program.

🔴 Leukemia & Hematopoietic Stem Cell Transplantation

For patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), or those requiring stem cell transplantation:

• Prof. Wang Jianmin (Changhai Hospital) — Director of the PLA Institute of Hematology and former Vice Chairman of the Chinese Medical Association Hematology Branch — one of China's most senior and experienced leukemia and transplantation authorities. Prof. Wang's decades of expertise in both the clinical management of leukemia and the science of hematopoietic stem cell transplantation — including matched sibling, matched unrelated, and haploidentical transplantation — make him the first choice for patients with high-risk leukemia or MDS requiring transplantation assessment.
• Prof. Li Junmin (Ruijin Hospital) — Vice President of the Chinese Medical Doctor Association Hematology Branch and President of the Chinese Geriatric Medicine Society Hematology Branch — China's foremost expert in leukemia immunotherapy and the treatment of blood cancers in older patients. For elderly patients with AML or ALL who cannot tolerate intensive chemotherapy, Prof. Li's expertise in low-intensity regimens (venetoclax + azacitidine), targeted therapy (FLT3, IDH inhibitors), and immunotherapy (blinatumomab, inotuzumab) offers effective treatment options that were previously unavailable to this population.

🌿 Integrative TCM-Western Medicine: Supportive Care & Non-Malignant Blood Disorders

For patients who wish to incorporate Traditional Chinese Medicine into their blood cancer care, or who have non-malignant blood disorders (aplastic anaemia, ITP, AIHA) where integrative TCM-Western treatment offers disease-modifying benefits:

• Prof. Zhou Yongming (Yueyang Hospital) — Director of the National Key Clinical Specialty in integrative TCM-Western hematology and China's recognized discipline leader in this field. Prof. Zhou's program is particularly valuable for patients with aplastic anaemia and ITP — where TCM herbal medicine has demonstrated disease-modifying efficacy — and for patients with leukemia or lymphoma who wish to use TCM to reduce chemotherapy toxicity, support bone marrow recovery, and improve quality of life during and after Western treatment.

Important Notes for International Patients

• Specialist clinic schedules change frequently. Before traveling to Shanghai, always confirm the latest appointment availability through the hospital's official app, website, or by contacting CMCS directly.
• Bring all prior medical records. For blood cancers, this includes bone marrow biopsy reports, cytogenetics, molecular profiling (NGS), flow cytometry, PET-CT, and a complete treatment history. Complete documentation enables the most accurate assessment and treatment planning.
• Remote pre-consultation is available. All specialists featured in this guide can review your records remotely before your arrival in Shanghai — enabling a preliminary treatment recommendation to be developed before you travel.
• A second opinion is always worthwhile. For patients with complex molecular profiles, treatment-resistant disease, or rare subtypes, CMCS can arrange consultations with multiple specialists to ensure you have the most comprehensive picture.

How CMCS Can Help

CMCS acts as your dedicated medical concierge, coordinating every aspect of your blood cancer care in Shanghai so you can focus on what matters most.

Our services include:

• ✅ Expert matching — we assess your case and recommend the most appropriate specialist(s) for your situation
• ✅ Direct appointment coordination with all featured specialists
• ✅ Bone marrow biopsy, molecular profiling, PET-CT, and treatment record translation and pre-consultation review
• ✅ CAR-T therapy and clinical trial eligibility assessment
• ✅ Second opinion facilitation
• ✅ Hospital admission and treatment scheduling support
• ✅ Accommodation and logistics coordination in Shanghai
• ✅ Post-treatment follow-up and remote check-in support

Contact CMCS

Ready to take the next step? Our team is here to help you find the right specialist and plan your blood cancer treatment in Shanghai.

📧 Email: contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 Website: www.medicalsh.com

CMCS — China Medical Concierge Shanghai. Connecting international patients with Shanghai's finest specialists.